(CYTK) Cytokinetics - NASDAQ

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 9.691m USD | Total Return: 122.7% in 12m

Muscle Activators, Muscle Inhibitors, Cardiac Pharmaceuticals
Total Rating 37
Safety 26
Buy Signal 0.85
Biotechnology
Industry Rotation: -8.7
Market Cap: 9.69B
Avg Turnover: 127M
Risk 3d forecast
Volatility53.0%
VaR 5th Pctl8.28%
VaR vs Median-5.81%
Reward TTM
Sharpe Ratio1.52
Rel. Str. IBD86.8
Rel. Str. Peer Group67.8
Character TTM
Beta1.212
Beta Downside0.956
Hurst Exponent0.461
Drawdowns 3y
Max DD72.39%
CAGR/Max DD0.39
CAGR/Mean DD0.68
EPS (Earnings per Share) EPS (Earnings per Share) of CYTK over the last years for every Quarter: "2021-06": -0.86, "2021-09": -0.95, "2021-12": -0.36, "2022-03": -1.02, "2022-06": -0.23, "2022-09": -1.28, "2022-12": -1.45, "2023-03": -1.38, "2023-06": -1.34, "2023-09": -1.35, "2023-12": -1.38, "2024-03": -1.33, "2024-06": -1.31, "2024-09": -1.36, "2024-12": -1.26, "2025-03": -1.36, "2025-06": -1.12, "2025-09": -1.54, "2025-12": -1.5, "2026-03": -1.67,
Last SUE: -0.11
Qual. Beats: 0
Revenue Revenue of CYTK over the last years for every Quarter: 2021-06: 2.843, 2021-09: 5.437, 2021-12: 55.6, 2022-03: 1.148, 2022-06: 88.968, 2022-09: 2.515, 2022-12: 1.957, 2023-03: 4.613, 2023-06: 0.867, 2023-09: 0.378, 2023-12: 1.672, 2024-03: 0.835, 2024-06: 0.249, 2024-09: 0.463, 2024-12: 16.927, 2025-03: 1.579, 2025-06: 66.769, 2025-09: 1.936, 2025-12: 17.755, 2026-03: 19.355,
Rev. CAGR: 241.32%
Rev. Trend: 80.4%
Last SUE: 0.45
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Interest Coverage Ratio -6.5 is critical

Beneish M-Score 0.27 > -1.5 - likely earnings manipulation

Altman Z'' -10.52 < 1.0 - financial distress zone

Tailwinds

Confidence, Tailwind, Pullback 52w

Description: CYTK Cytokinetics

Cytokinetics, Incorporated is a South San Francisco-based biopharmaceutical company specializing in the discovery and commercialization of muscle activators and inhibitors. Its primary clinical focus is on cardiac myosin modulation to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and heart failure. The firm’s current portfolio includes MYQORZO, alongside late-stage candidates like aficamten and omecamtiv mecarbil.

The biotechnology sector typically operates on a high-risk, high-reward business model characterized by significant research and development (R&D) expenditure and long regulatory approval cycles. Companies in this sub-industry often rely on intellectual property protections and orphan drug designations to secure market exclusivity for novel therapies.

For a deeper dive into these clinical milestones and financial metrics, you may find ValueRay a helpful resource for further research.

Headlines to Watch Out For
  • FDA approval and US commercial launch of aficamten for hypertrophic cardiomyopathy
  • Clinical trial results for omecamtiv mecarbil drive heart failure treatment valuation
  • Potential acquisition interest from large-cap pharmaceutical companies boosts equity volatility
  • Research and development expenses for early-stage cardiac myosin inhibitors impact cash runway
  • Market competition with Bristol Myers Squibb’s Camzyos influences cardiac drug market share
Piotroski VR-10 (Strict) 1.5
Net Income: -829.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.57 > 0.02 and ΔFCF/TA -15.96 > 1.0
NWC/Revenue: 605.1% < 20% (prev 4.14k%; Δ -3.54k% < -1%)
CFO/TA -0.41 > 3% & CFO -523.8m > Net Income -829.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.21 > 1.5 & < 3
Outstanding Shares: last quarter (123.3m) vs 12m ago 4.03% < -2%
Gross Margin: 90.34% > 18% (prev -1.76k%; Δ 1.85k% > 0.5%)
Asset Turnover: 8.34% > 50% (prev 1.52%; Δ 6.82% > 0%)
Interest Coverage Ratio: -6.53 > 6 (EBIT TTM -745.7m / Interest Expense TTM 114.3m)
Altman Z'' -10.52
A: 0.50 (Total Current Assets 839.5m - Total Current Liabilities 199.2m) / Total Assets 1.27b
B: -2.90 (Retained Earnings -3.69b / Total Assets 1.27b)
C: -0.59 (EBIT TTM -745.7m / Avg Total Assets 1.27b)
D: -0.39 (Book Value of Equity -826.6m / Total Liabilities 2.10b)
Altman-Z'' = -10.52 = D
Beneish M 0.27
DSRI: 0.62 (Receivables 6.83m/2.01m, Revenue 105.8m/19.2m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.68 (AQ_t 0.22 / AQ_t-1 0.13)
SGI: 5.51 (Revenue 105.8m / 19.2m)
TATA: -0.24 (NI -829.6m - CFO -523.8m) / TA 1.27b)
Beneish M = 0.27 (Cap -4..+1) = D
What is the price of CYTK shares?

As of June 17, 2026, the stock is trading at USD 75.21 with a total of 3,925,461 shares traded.
Over the past week, the price has changed by +9.88%, over one month by +0.04%, over three months by +23.64% and over the past year by +122.65%.

Is CYTK a buy, sell or hold?

Cytokinetics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CYTK.

  • StrongBuy: 9
  • Buy: 9
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CYTK price?
Analysts Target Price 104.7 39.2%
Cytokinetics (CYTK) - Fundamental Data Overview as of 16 June 2026
Market Cap USD = 9.69b (9.69b USD * 1.0 USD.USD)
P/E Forward = 117.6471
P/S = 91.5873
P/B = 60.3093
P/EG = -0.42
Revenue TTM = 105.8m USD
EBIT TTM = -745.7m USD
EBITDA TTM = -734.7m USD
Long Term Debt = 1.12b USD (from longTermDebt, last quarter)
Short Term Debt = 65.8m USD (from shortTermDebt, last quarter)
Debt = 1.41b USD (from shortLongTermDebtTotal, last quarter) + Leases 126.2m
Net Debt = 952.8m USD (calculated: Debt 1.41b - CCE 462.2m)
Enterprise Value = 10.6b USD (9.69b + Debt 1.41b - CCE 462.2m)
Interest Coverage Ratio = -6.53 (Ebit TTM -745.7m / Interest Expense TTM 114.3m)
EV/FCF = -14.69x (Enterprise Value 10.6b / FCF TTM -724.3m)
FCF Yield = -6.81% (FCF TTM -724.3m / Enterprise Value 10.6b)
 FCF Margin = -684.5% (FCF TTM -724.3m / Revenue TTM 105.8m)
 Net Margin = -784.0% (Net Income TTM -829.6m / Revenue TTM 105.8m)
 Gross Margin = 90.34% ((Revenue TTM 105.8m - Cost of Revenue TTM 10.2m) / Revenue TTM)
Gross Margin QoQ = 87.64% (prev 83.89%)
Tobins Q-Ratio = 8.36 (Enterprise Value 10.6b / Total Assets 1.27b)
Interest Expense / Debt = 8.08% (Interest Expense 114.3m / Debt 1.41b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -589.1m (EBIT -745.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.75 (Total Current Assets 839.5m / Total Current Liabilities 223.9m)
 Debt / Equity = -1.71 (negative equity) (Debt 1.41b / totalStockholderEquity, last quarter -826.6m)
 Debt / EBITDA = -1.30 (negative EBITDA) (Net Debt 952.8m / EBITDA -734.7m)
 Debt / FCF = -1.32 (negative FCF - burning cash) (Net Debt 952.8m / FCF TTM -724.3m)
 Total Stockholder Equity = -594.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -65.39% (Net Income -829.6m / Total Assets 1.27b)
 RoE = 139.7% (negative equity) (Net Income TTM -829.6m / Total Stockholder Equity -594.0m)
 RoCE = -142.4% (out of range, set to none) (EBIT -745.7m / Capital Employed (Equity -594.0m + L.T.Debt 1.12b))
 RoIC = -51.91% (negative operating profit) (NOPAT -589.1m / Invested Capital 1.13b)
 WACC = 9.76% (E(9.69b)/V(11.1b) * Re(10.25%) + D(1.41b)/V(11.1b) * Rd(8.08%) * (1-Tc(0.21)))
Discount Rate = 10.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.20%
 [DCF] Fair Price = unknown (Cash Flow -724.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.11 | # QB: 0
Revenue Correlation: 80.42 | Revenue CAGR: 241.3% | SUE: 0.45 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.64 | Chg30d=+2.15% | Revisions=+38% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-1.59 | Chg30d=+3.63% | Revisions=+29% | Analysts=15
EPS current Year (2026-12-31): EPS=-6.43 | Chg30d=+2.20% | Revisions=+18% | GrowthEPS=+1.6% | GrowthRev=+24.1%
EPS next Year (2027-12-31): EPS=-4.75 | Chg30d=+4.41% | Revisions=+25% | GrowthEPS=+26.1% | GrowthRev=+254.5%
[Analyst] Revisions Ratio: +38%